Project Grant R01AG087323
Award Date
12/15/24
Completion Date
11/30/29
Dollars Obligated
$842K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
This $636,000 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to evaluate the use of novel, orally bioavailable small molecule inhibitors of the NOX2 protein as a potential therapeutic strategy for treating Alzheimer's disease (AD) and related dementias. The University of Pittsburgh will conduct studies in an established AD mouse model to assess the impact of the NOX2 inhibitors CPP11G and CPP11H on key pathological features of AD, including...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
The National Institute on Aging awarded a $1,198,947 Project Grant under the Aging Research program (CFDA 93.866) to The Regents of the University of California, San Francisco (UCSF) on September 30, 2023. The grant will fund research to investigate the neuroprotective effects of a blood-derived enzyme called GPLD1 on Alzheimer's disease pathology. Specifically, the project aims to: 1) examine the relationships between GPLD1, physical activity, immunovascular function, and cognition in older...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $804,450 provides funding to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, to investigate the mechanisms behind selective neuronal dysfunction caused by the Alzheimer's disease genetic risk factor ApoE4. The research aims to 1) validate the protective effects of the protein NELL2 in hippocampal excitatory neurons of ApoE4 mouse models,...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,929,011 to The Regents of the University of California, San Francisco to conduct a longitudinal, multimodal imaging study. The study aims to elucidate the role of neuronal dysfunction and hyperexcitability in the early biological progression of Alzheimer's disease. The research will identify the earliest manifestations of neural circuit hyperexcitability that predict the...
This $679,424 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports preclinical studies to evaluate the efficacy of a novel nanoligomer treatment for reducing neuroinflammation and protecting against cognitive decline in mouse models of brain aging and Alzheimer's disease. The research aims to determine the ideal application of the NF-kB/NLRP3-targeted nanoligomer treatment, whether for prevention during aging or treatment of pathology, and to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $452,550 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of reactive astrogliosis, specifically the upregulation of the glial fibrillary acidic protein (GFAP) in astrocytes, on synaptic dysfunction and loss in Alzheimer's disease. The researchers will examine how GFAP upregulation in reactive astrocytes impacts the protein...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant under the Aging Research program (CFDA 93.866) to Florida International University (FIU). The 2-year award, effective from September 15, 2024 to August 31, 2026, aims to develop a novel biotherapeutic nanogel system to target key biomarkers of Alzheimer's disease (AD). The proposed nanogels are designed to enhance blood-brain barrier penetration, inhibit amyloid-beta aggregation, and mitigate oxidative stress and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This $816,661 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) supports research to comprehensively map the impact of tau pathology on the proteome and measure the functional consequences in mouse models and human iPSC tauopathy models. The research aims to deepen the understanding of molecular mechanisms in Alzheimer's disease and related dementias, with the potential to identify novel therapeutic targets. The grant was awarded to The Regents of the...